Ebola vaccines for mass immunisation in affected regions

Lancet Infect Dis. 2022 Jan;22(1):8-10. doi: 10.1016/S1473-3099(21)00226-7. Epub 2021 Sep 13.

Authors

Selidji Todagbe Agnandji¹, Marguerite Massinga Loembe²

Affiliations

¹ Centre de Recherches Médicales de Lambaréné, Lambaréné BP 242, Gabon; Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany; Fondation pour la Recherche Scientifique, Cotonou, Bénin. Electronic address: agnandjis@cermel.org.
² Africa Centers for Disease Control and Prevention, Adis-Abeba, Ethiopia.

PMID: 34529960
DOI: 10.1016/S1473-3099(21)00226-7

No abstract available

MeSH terms

Africa / epidemiology
Clinical Trials as Topic
Democratic Republic of the Congo / epidemiology
Disease Outbreaks / prevention & control
Ebola Vaccines / administration & dosage
Ebola Vaccines / immunology*
Ebolavirus / immunology*
Ebolavirus / pathogenicity
Hemorrhagic Fever, Ebola / epidemiology
Hemorrhagic Fever, Ebola / immunology
Hemorrhagic Fever, Ebola / prevention & control*
Humans
Mass Vaccination*

Substances

Ebola Vaccines